Loading…
Equivalent Outcomes for Pediatric Heart Transplantation Recipients: ABO‐Blood Group Incompatible versus ABO‐Compatible
ABO‐blood group incompatible infant heart transplantation has had excellent short‐term outcomes. Uncertainties about long‐term outcomes have been a barrier to the adoption of this strategy worldwide. We report a nonrandomized comparison of clinical outcomes over 10 years of the largest cohort of ABO...
Saved in:
| Published in: | American journal of transplantation 2010-02, Vol.10 (2), p.389-397 |
|---|---|
| Main Authors: | , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c3984-49b9e17e06229770bfc016598a70111959da58219e91d43fc4af3b847ccf90de3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c3984-49b9e17e06229770bfc016598a70111959da58219e91d43fc4af3b847ccf90de3 |
| container_end_page | 397 |
| container_issue | 2 |
| container_start_page | 389 |
| container_title | American journal of transplantation |
| container_volume | 10 |
| creator | Dipchand, A. I. Pollock BarZiv, S. M. Manlhiot, C. West, L. J. VanderVliet, M. McCrindle, B. W. |
| description | ABO‐blood group incompatible infant heart transplantation has had excellent short‐term outcomes. Uncertainties about long‐term outcomes have been a barrier to the adoption of this strategy worldwide. We report a nonrandomized comparison of clinical outcomes over 10 years of the largest cohort of ABO‐incompatible recipients. ABO‐incompatible (n = 35) and ABO‐compatible (n = 45) infant heart transplantation recipients (≤14 months old, 1996–2006) showed no important differences in pretransplantation characteristics. There was no difference in incidence of and time to moderate acute cellular rejection. Despite either the presence (seven patients) or development (eight patients) of donor‐specific antibodies against blood group antigens, in only two ABO‐incompatible patients were these antibodies implicated in antibody‐mediated rejection (which occurred early posttransplantation, was easily managed and did not recur in follow‐up). Occurrence of graft vasculopathy (11%), malignancy (11%) and freedom from severe renal dysfunction were identical in both groups. Survival was identical (74% at 7 years posttransplantation). ABO‐blood group incompatible heart transplantation has excellent outcomes that are indistinguishable from those of the ABO‐compatible population and there is no clinical justification for withholding this lifesaving strategy from all infants listed for heart transplantation. Further studies into observed differing responses in the development of donor‐specific isohemagglutinins and the implications for graft accommodation are warranted.
Comparison of two contemporary pediatric populations who received either ABO‐compatible or ABO‐incompatible heart transplants found that medium‐term outcomes were indistinguishable, and the use of ABO‐incompatible listing improved waitlist survival. |
| doi_str_mv | 10.1111/j.1600-6143.2009.02934.x |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_733913167</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>733913167</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3984-49b9e17e06229770bfc016598a70111959da58219e91d43fc4af3b847ccf90de3</originalsourceid><addsrcrecordid>eNqNkMtu3CAUhlGVqLm0r1CxibIah5uNqZTFZJRbFWmqarpGGB9LjDzGATtNuuoj9Bn7JMWZ6WRbNhzB958DH0KYkoymdbHOaEHIrKCCZ4wQlRGmuMie36Hj_cXBvub5ETqJcU0Ilaxk79FRyghaFvIY_bx-HN2TaaEb8HIcrN9AxI0P-CvUzgzBWXwHJgx4FUwX-9Z0gxmc7_A3sK53KRY_4_nV8s-v31et9zW-DX7s8X2XOvWJrFrATxDiGHfUYn_-AR02po3wcbefou8316vF3exheXu_mD_MLFelmAlVKaASSMGYkpJUjSW0yFVpJEkuVK5qk5eMKlC0FryxwjS8KoW0tlGkBn6Kzrd9--AfR4iD3rhooU1_AT9GLTlXlNNCJrLckjb4GAM0ug9uY8KLpkRP4vVaT0715FdP4vWreP2cop92Q8ZqA_U--M90As52gInWtE3SaV1845hgrOR54i633A_Xwst_P0DPv6ymiv8FL8mg2w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>733913167</pqid></control><display><type>article</type><title>Equivalent Outcomes for Pediatric Heart Transplantation Recipients: ABO‐Blood Group Incompatible versus ABO‐Compatible</title><source>Wiley-Blackwell Journals</source><source>ScienceDirect Additional Titles</source><creator>Dipchand, A. I. ; Pollock BarZiv, S. M. ; Manlhiot, C. ; West, L. J. ; VanderVliet, M. ; McCrindle, B. W.</creator><creatorcontrib>Dipchand, A. I. ; Pollock BarZiv, S. M. ; Manlhiot, C. ; West, L. J. ; VanderVliet, M. ; McCrindle, B. W.</creatorcontrib><description>ABO‐blood group incompatible infant heart transplantation has had excellent short‐term outcomes. Uncertainties about long‐term outcomes have been a barrier to the adoption of this strategy worldwide. We report a nonrandomized comparison of clinical outcomes over 10 years of the largest cohort of ABO‐incompatible recipients. ABO‐incompatible (n = 35) and ABO‐compatible (n = 45) infant heart transplantation recipients (≤14 months old, 1996–2006) showed no important differences in pretransplantation characteristics. There was no difference in incidence of and time to moderate acute cellular rejection. Despite either the presence (seven patients) or development (eight patients) of donor‐specific antibodies against blood group antigens, in only two ABO‐incompatible patients were these antibodies implicated in antibody‐mediated rejection (which occurred early posttransplantation, was easily managed and did not recur in follow‐up). Occurrence of graft vasculopathy (11%), malignancy (11%) and freedom from severe renal dysfunction were identical in both groups. Survival was identical (74% at 7 years posttransplantation). ABO‐blood group incompatible heart transplantation has excellent outcomes that are indistinguishable from those of the ABO‐compatible population and there is no clinical justification for withholding this lifesaving strategy from all infants listed for heart transplantation. Further studies into observed differing responses in the development of donor‐specific isohemagglutinins and the implications for graft accommodation are warranted.
Comparison of two contemporary pediatric populations who received either ABO‐compatible or ABO‐incompatible heart transplants found that medium‐term outcomes were indistinguishable, and the use of ABO‐incompatible listing improved waitlist survival.</description><identifier>ISSN: 1600-6135</identifier><identifier>EISSN: 1600-6143</identifier><identifier>DOI: 10.1111/j.1600-6143.2009.02934.x</identifier><identifier>PMID: 20041867</identifier><language>eng</language><publisher>Malden, USA: Blackwell Publishing Inc</publisher><subject>ABO Blood-Group System - immunology ; ABO incompatibility ; Antibodies - immunology ; Antineoplastic Combined Chemotherapy Protocols ; Biological and medical sciences ; Bleomycin ; Blood Group Antigens - immunology ; Child ; General aspects ; Graft Rejection - immunology ; heart transplantation ; Heart Transplantation - immunology ; Heart Transplantation - mortality ; Hemagglutinins - immunology ; Humans ; Infant ; Medical sciences ; Methotrexate ; pediatric transplantation ; Pediatrics ; rejection ; Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases ; Tissue Donors - statistics & numerical data ; Treatment Outcome ; Vincristine</subject><ispartof>American journal of transplantation, 2010-02, Vol.10 (2), p.389-397</ispartof><rights>2009 The Authors Journal compilation © 2009 The American Society of Transplantation and the American Society of Transplant Surgeons</rights><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3984-49b9e17e06229770bfc016598a70111959da58219e91d43fc4af3b847ccf90de3</citedby><cites>FETCH-LOGICAL-c3984-49b9e17e06229770bfc016598a70111959da58219e91d43fc4af3b847ccf90de3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1600-6143.2009.02934.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1600-6143.2009.02934.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>315,786,790,27957,27958,50923,51032</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=22422835$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20041867$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Dipchand, A. I.</creatorcontrib><creatorcontrib>Pollock BarZiv, S. M.</creatorcontrib><creatorcontrib>Manlhiot, C.</creatorcontrib><creatorcontrib>West, L. J.</creatorcontrib><creatorcontrib>VanderVliet, M.</creatorcontrib><creatorcontrib>McCrindle, B. W.</creatorcontrib><title>Equivalent Outcomes for Pediatric Heart Transplantation Recipients: ABO‐Blood Group Incompatible versus ABO‐Compatible</title><title>American journal of transplantation</title><addtitle>Am J Transplant</addtitle><description>ABO‐blood group incompatible infant heart transplantation has had excellent short‐term outcomes. Uncertainties about long‐term outcomes have been a barrier to the adoption of this strategy worldwide. We report a nonrandomized comparison of clinical outcomes over 10 years of the largest cohort of ABO‐incompatible recipients. ABO‐incompatible (n = 35) and ABO‐compatible (n = 45) infant heart transplantation recipients (≤14 months old, 1996–2006) showed no important differences in pretransplantation characteristics. There was no difference in incidence of and time to moderate acute cellular rejection. Despite either the presence (seven patients) or development (eight patients) of donor‐specific antibodies against blood group antigens, in only two ABO‐incompatible patients were these antibodies implicated in antibody‐mediated rejection (which occurred early posttransplantation, was easily managed and did not recur in follow‐up). Occurrence of graft vasculopathy (11%), malignancy (11%) and freedom from severe renal dysfunction were identical in both groups. Survival was identical (74% at 7 years posttransplantation). ABO‐blood group incompatible heart transplantation has excellent outcomes that are indistinguishable from those of the ABO‐compatible population and there is no clinical justification for withholding this lifesaving strategy from all infants listed for heart transplantation. Further studies into observed differing responses in the development of donor‐specific isohemagglutinins and the implications for graft accommodation are warranted.
Comparison of two contemporary pediatric populations who received either ABO‐compatible or ABO‐incompatible heart transplants found that medium‐term outcomes were indistinguishable, and the use of ABO‐incompatible listing improved waitlist survival.</description><subject>ABO Blood-Group System - immunology</subject><subject>ABO incompatibility</subject><subject>Antibodies - immunology</subject><subject>Antineoplastic Combined Chemotherapy Protocols</subject><subject>Biological and medical sciences</subject><subject>Bleomycin</subject><subject>Blood Group Antigens - immunology</subject><subject>Child</subject><subject>General aspects</subject><subject>Graft Rejection - immunology</subject><subject>heart transplantation</subject><subject>Heart Transplantation - immunology</subject><subject>Heart Transplantation - mortality</subject><subject>Hemagglutinins - immunology</subject><subject>Humans</subject><subject>Infant</subject><subject>Medical sciences</subject><subject>Methotrexate</subject><subject>pediatric transplantation</subject><subject>Pediatrics</subject><subject>rejection</subject><subject>Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases</subject><subject>Tissue Donors - statistics & numerical data</subject><subject>Treatment Outcome</subject><subject>Vincristine</subject><issn>1600-6135</issn><issn>1600-6143</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><recordid>eNqNkMtu3CAUhlGVqLm0r1CxibIah5uNqZTFZJRbFWmqarpGGB9LjDzGATtNuuoj9Bn7JMWZ6WRbNhzB958DH0KYkoymdbHOaEHIrKCCZ4wQlRGmuMie36Hj_cXBvub5ETqJcU0Ilaxk79FRyghaFvIY_bx-HN2TaaEb8HIcrN9AxI0P-CvUzgzBWXwHJgx4FUwX-9Z0gxmc7_A3sK53KRY_4_nV8s-v31et9zW-DX7s8X2XOvWJrFrATxDiGHfUYn_-AR02po3wcbefou8316vF3exheXu_mD_MLFelmAlVKaASSMGYkpJUjSW0yFVpJEkuVK5qk5eMKlC0FryxwjS8KoW0tlGkBn6Kzrd9--AfR4iD3rhooU1_AT9GLTlXlNNCJrLckjb4GAM0ug9uY8KLpkRP4vVaT0715FdP4vWreP2cop92Q8ZqA_U--M90As52gInWtE3SaV1845hgrOR54i633A_Xwst_P0DPv6ymiv8FL8mg2w</recordid><startdate>201002</startdate><enddate>201002</enddate><creator>Dipchand, A. I.</creator><creator>Pollock BarZiv, S. M.</creator><creator>Manlhiot, C.</creator><creator>West, L. J.</creator><creator>VanderVliet, M.</creator><creator>McCrindle, B. W.</creator><general>Blackwell Publishing Inc</general><general>Wiley</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201002</creationdate><title>Equivalent Outcomes for Pediatric Heart Transplantation Recipients: ABO‐Blood Group Incompatible versus ABO‐Compatible</title><author>Dipchand, A. I. ; Pollock BarZiv, S. M. ; Manlhiot, C. ; West, L. J. ; VanderVliet, M. ; McCrindle, B. W.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3984-49b9e17e06229770bfc016598a70111959da58219e91d43fc4af3b847ccf90de3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>ABO Blood-Group System - immunology</topic><topic>ABO incompatibility</topic><topic>Antibodies - immunology</topic><topic>Antineoplastic Combined Chemotherapy Protocols</topic><topic>Biological and medical sciences</topic><topic>Bleomycin</topic><topic>Blood Group Antigens - immunology</topic><topic>Child</topic><topic>General aspects</topic><topic>Graft Rejection - immunology</topic><topic>heart transplantation</topic><topic>Heart Transplantation - immunology</topic><topic>Heart Transplantation - mortality</topic><topic>Hemagglutinins - immunology</topic><topic>Humans</topic><topic>Infant</topic><topic>Medical sciences</topic><topic>Methotrexate</topic><topic>pediatric transplantation</topic><topic>Pediatrics</topic><topic>rejection</topic><topic>Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases</topic><topic>Tissue Donors - statistics & numerical data</topic><topic>Treatment Outcome</topic><topic>Vincristine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dipchand, A. I.</creatorcontrib><creatorcontrib>Pollock BarZiv, S. M.</creatorcontrib><creatorcontrib>Manlhiot, C.</creatorcontrib><creatorcontrib>West, L. J.</creatorcontrib><creatorcontrib>VanderVliet, M.</creatorcontrib><creatorcontrib>McCrindle, B. W.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>American journal of transplantation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dipchand, A. I.</au><au>Pollock BarZiv, S. M.</au><au>Manlhiot, C.</au><au>West, L. J.</au><au>VanderVliet, M.</au><au>McCrindle, B. W.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Equivalent Outcomes for Pediatric Heart Transplantation Recipients: ABO‐Blood Group Incompatible versus ABO‐Compatible</atitle><jtitle>American journal of transplantation</jtitle><addtitle>Am J Transplant</addtitle><date>2010-02</date><risdate>2010</risdate><volume>10</volume><issue>2</issue><spage>389</spage><epage>397</epage><pages>389-397</pages><issn>1600-6135</issn><eissn>1600-6143</eissn><notes>ObjectType-Article-1</notes><notes>SourceType-Scholarly Journals-1</notes><notes>ObjectType-Feature-2</notes><notes>content type line 23</notes><abstract>ABO‐blood group incompatible infant heart transplantation has had excellent short‐term outcomes. Uncertainties about long‐term outcomes have been a barrier to the adoption of this strategy worldwide. We report a nonrandomized comparison of clinical outcomes over 10 years of the largest cohort of ABO‐incompatible recipients. ABO‐incompatible (n = 35) and ABO‐compatible (n = 45) infant heart transplantation recipients (≤14 months old, 1996–2006) showed no important differences in pretransplantation characteristics. There was no difference in incidence of and time to moderate acute cellular rejection. Despite either the presence (seven patients) or development (eight patients) of donor‐specific antibodies against blood group antigens, in only two ABO‐incompatible patients were these antibodies implicated in antibody‐mediated rejection (which occurred early posttransplantation, was easily managed and did not recur in follow‐up). Occurrence of graft vasculopathy (11%), malignancy (11%) and freedom from severe renal dysfunction were identical in both groups. Survival was identical (74% at 7 years posttransplantation). ABO‐blood group incompatible heart transplantation has excellent outcomes that are indistinguishable from those of the ABO‐compatible population and there is no clinical justification for withholding this lifesaving strategy from all infants listed for heart transplantation. Further studies into observed differing responses in the development of donor‐specific isohemagglutinins and the implications for graft accommodation are warranted.
Comparison of two contemporary pediatric populations who received either ABO‐compatible or ABO‐incompatible heart transplants found that medium‐term outcomes were indistinguishable, and the use of ABO‐incompatible listing improved waitlist survival.</abstract><cop>Malden, USA</cop><pub>Blackwell Publishing Inc</pub><pmid>20041867</pmid><doi>10.1111/j.1600-6143.2009.02934.x</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1600-6135 |
| ispartof | American journal of transplantation, 2010-02, Vol.10 (2), p.389-397 |
| issn | 1600-6135 1600-6143 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_733913167 |
| source | Wiley-Blackwell Journals; ScienceDirect Additional Titles |
| subjects | ABO Blood-Group System - immunology ABO incompatibility Antibodies - immunology Antineoplastic Combined Chemotherapy Protocols Biological and medical sciences Bleomycin Blood Group Antigens - immunology Child General aspects Graft Rejection - immunology heart transplantation Heart Transplantation - immunology Heart Transplantation - mortality Hemagglutinins - immunology Humans Infant Medical sciences Methotrexate pediatric transplantation Pediatrics rejection Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases Tissue Donors - statistics & numerical data Treatment Outcome Vincristine |
| title | Equivalent Outcomes for Pediatric Heart Transplantation Recipients: ABO‐Blood Group Incompatible versus ABO‐Compatible |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-21T14%3A57%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Equivalent%20Outcomes%20for%20Pediatric%20Heart%20Transplantation%20Recipients:%20ABO%E2%80%90Blood%20Group%20Incompatible%20versus%20ABO%E2%80%90Compatible&rft.jtitle=American%20journal%20of%20transplantation&rft.au=Dipchand,%20A.%20I.&rft.date=2010-02&rft.volume=10&rft.issue=2&rft.spage=389&rft.epage=397&rft.pages=389-397&rft.issn=1600-6135&rft.eissn=1600-6143&rft_id=info:doi/10.1111/j.1600-6143.2009.02934.x&rft_dat=%3Cproquest_cross%3E733913167%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3984-49b9e17e06229770bfc016598a70111959da58219e91d43fc4af3b847ccf90de3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=733913167&rft_id=info:pmid/20041867&rfr_iscdi=true |